Literature DB >> 26738860

The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer.

Hai Hu1,2, Jun-Jie Hang1,2, Ting Han1,2, Meng Zhuo1,2, Feng Jiao3,4, Li-Wei Wang5,6.   

Abstract

Macrophages play a critical role in the initiation and progression of various solid tumors. However, their prognostic significance in pancreatic ductal adenocarcinoma (PDAC) is poorly understood. This study investigated the distribution patterns of macrophages in PDAC and possible association with the overall survival (OS). We found significant differences in macrophage density (identified by CD68 and CD163 immunopositivity; p < 0.001 for both) between primary cancer and paired adjacent normal tissues. Most macrophages in cancerous pancreatic tissues were located in the stroma rather than the islets (p = 0.032 and p < 0.001). We also demonstrated that a high total macrophage density (characterized by CD68 immunopositivity) correlated with an absence of jaundice before surgery (p = 0.03) and that a high density of M2 macrophages (characterized by CD163 immunopositivity) in the stroma strongly correlated with the tumors located in the tail and body of the pancreas (p = 0.04). In addition, OS was shorter in patients with high-density M2 macrophage infiltration than in those with low-density M2 macrophage infiltration (p = 0.012). Moreover, multivariate analysis revealed that dense M2 macrophage infiltration into the stroma was an independent prognostic factor for PDAC patients (p = 0.02).

Entities:  

Keywords:  Immunohistochemistry; Macrophage; Pancreatic ductal adenocarcinoma; Prognosis

Mesh:

Substances:

Year:  2016        PMID: 26738860     DOI: 10.1007/s13277-015-4741-z

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  27 in total

Review 1.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

Review 2.  Origin and turnover of monocytes and macrophages.

Authors:  R van Furth
Journal:  Curr Top Pathol       Date:  1989

Review 3.  Macrophages and therapeutic resistance in cancer.

Authors:  Brian Ruffell; Lisa M Coussens
Journal:  Cancer Cell       Date:  2015-04-06       Impact factor: 31.743

4.  Impact of tumor-associated macrophages on invasive ductal carcinoma of the pancreas head.

Authors:  Kiyoshi Yoshikawa; Shuichi Mitsunaga; Taira Kinoshita; Masaru Konishi; Shinichiro Takahashi; Naoto Gotohda; Yuichiro Kato; Masaki Aizawa; Atsushi Ochiai
Journal:  Cancer Sci       Date:  2012-10-04       Impact factor: 6.716

5.  CD163 positive subsets of blood dendritic cells: the scavenging macrophage receptors CD163 and CD91 are coexpressed on human dendritic cells and monocytes.

Authors:  Maciej Bogdan Maniecki; Holger Jon Møller; Søren Kragh Moestrup; Bjarne Kuno Møller
Journal:  Immunobiology       Date:  2006-07-20       Impact factor: 3.144

6.  Annual report on status of cancer in China, 2011.

Authors:  Wanqing Chen; Rongshou Zheng; Hongmei Zeng; Siwei Zhang; Jie He
Journal:  Chin J Cancer Res       Date:  2015-02       Impact factor: 5.087

7.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

8.  Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population.

Authors:  Damya Laoui; Eva Van Overmeire; Giusy Di Conza; Chiara Aldeni; Jiri Keirsse; Yannick Morias; Kiavash Movahedi; Isabelle Houbracken; Elio Schouppe; Yvon Elkrim; Oussama Karroum; Bénédicte Jordan; Peter Carmeliet; Conny Gysemans; Patrick De Baetselier; Massimiliano Mazzone; Jo A Van Ginderachter
Journal:  Cancer Res       Date:  2013-11-12       Impact factor: 12.701

9.  Long noncoding RNA MALAT-1 enhances stem cell-like phenotypes in pancreatic cancer cells.

Authors:  Feng Jiao; Hai Hu; Ting Han; Cuncun Yuan; Lei Wang; Ziliang Jin; Zhen Guo; Liwei Wang
Journal:  Int J Mol Sci       Date:  2015-03-24       Impact factor: 5.923

10.  Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer.

Authors:  Y Ino; R Yamazaki-Itoh; K Shimada; M Iwasaki; T Kosuge; Y Kanai; N Hiraoka
Journal:  Br J Cancer       Date:  2013-02-05       Impact factor: 7.640

View more
  74 in total

1.  Targeting tumor-intrinsic hexosamine biosynthesis sensitizes pancreatic cancer to anti-PD1 therapy.

Authors:  Nikita S Sharma; Vineet K Gupta; Vanessa T Garrido; Roey Hadad; Brittany C Durden; Kousik Kesh; Bhuwan Giri; Anthony Ferrantella; Vikas Dudeja; Ashok Saluja; Sulagna Banerjee
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 2.  Tumor-derived exosomes in the regulation of macrophage polarization.

Authors:  Mirza S Baig; Anjali Roy; Sajjan Rajpoot; Dongfang Liu; Rajkumar Savai; Sreeparna Banerjee; Manabu Kawada; Syed M Faisal; Rohit Saluja; Uzma Saqib; Tomokazu Ohishi; Kishore K Wary
Journal:  Inflamm Res       Date:  2020-03-11       Impact factor: 4.575

3.  Stratification of Pancreatic Ductal Adenocarcinoma: Combinatorial Genetic, Stromal, and Immunologic Markers.

Authors:  Erik S Knudsen; Paris Vail; Uthra Balaji; Hoai Ngo; Ihab W Botros; Vladimir Makarov; Nadeem Riaz; Vinod Balachandran; Steven Leach; Debrah M Thompson; Timothy A Chan; Agnieszka K Witkiewicz
Journal:  Clin Cancer Res       Date:  2017-03-27       Impact factor: 12.531

4.  An Overview of Advances in Cell-Based Cancer Immunotherapies Based on the Multiple Immune-Cancer Cell Interactions.

Authors:  Jialing Zhang; Stephan S Späth; Sherman M Weissman; Samuel G Katz
Journal:  Methods Mol Biol       Date:  2020

Review 5.  Signaling in the microenvironment of pancreatic cancer: Transmitting along the nerve.

Authors:  Noelle Jurcak; Lei Zheng
Journal:  Pharmacol Ther       Date:  2019-04-29       Impact factor: 12.310

6.  VentX expression in tumor-associated macrophages promotes phagocytosis and immunity against pancreatic cancers.

Authors:  Yi Le; Hong Gao; William Richards; Lei Zhao; Ronald Bleday; Thomas Clancy; Zhenglun Zhu
Journal:  JCI Insight       Date:  2020-07-23

Review 7.  Local and systemic immunosuppression in pancreatic cancer: Targeting the stalwarts in tumor's arsenal.

Authors:  Clara S Mundry; Kirsten C Eberle; Pankaj K Singh; Michael A Hollingsworth; Kamiya Mehla
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-06-21       Impact factor: 10.680

8.  The interplay of growth differentiation factor 15 (GDF15) expression and M2 macrophages during prostate carcinogenesis.

Authors:  Sudha M Sadasivan; Yalei Chen; Nilesh S Gupta; Xiaoxia Han; Kevin R Bobbitt; Dhananjay A Chitale; Sean R Williamson; Andrew G Rundle; Deliang Tang; Benjamin A Rybicki
Journal:  Carcinogenesis       Date:  2020-08-12       Impact factor: 4.944

Review 9.  Regulation and modulation of antitumor immunity in pancreatic cancer.

Authors:  Joshua Leinwand; George Miller
Journal:  Nat Immunol       Date:  2020-08-17       Impact factor: 25.606

10.  DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization.

Authors:  Courtney W Houchen; Parthasarathy Chandrakesan; Janani Panneerselvam; Randal May; Nathaniel Weygant; Dongfeng Qu; William R Berry; Kamille Pitts; Ben Z Stanger; Chinthalapally V Rao; Michael S Bronze
Journal:  Mol Cancer Ther       Date:  2020-05-05       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.